We would love to hear your thoughts about our site and services, please take our survey here.
Its not. She was treated with immunotherapy
Should add to this that Avacta also have their own form of ADCs but instead of antibody they intend to use affimer, with preCision linker to chemical warhead. Combining both technologies.
Are we selling at a discount? Is it not just that the average price over q1 is low compared to todays prices because price didnt spike until mid feb?
Hopefully thats exactly what they mean.
Should also point out that the amino acid sequence of murine fap and human has very high homology including key residues responsible for cleavage
Quite a few people asking what is new in this poster. For me the mew info is the inclusion of rat and dog data which indicates that the linker is cleaved across species. Most importantly though is the use of recombinant human fap in vitro also demonstrates that human fap can also cleave. This hasnt been demonstrated previously in my view as the mouse model may have only been due to murine fap produced by fibroblasts surrounding the tumour. The PDX model of osteosarcoma which had previously been treated with dox is also extremely encouraging. None of this is a substitute for human trials of course but its building a very strong case for ava6000 and the precision tech in general. Bought more on thw back of this data this morning. My main concern had always been that human fap may not cleave the linker as well as murine.
perhaps the next acquisition?
https://www.abingdonhealth.com/1m-funding-quantitative-lateral-flow-smartphone-reader/
Could be interesting from avacta standpoint
great video, really informative. Thanks for posting
Clinical validation - To date we haven't been able to state what % sensitivity is because we haven't done any clinical testing. Condor programme will provide access to samples and the testing will now be performed quite rapidly. Access to samples has become quite difficult of late, especially with so many companies wanting to do tests. Also when I say rapidly I mean in the terms of how quick science moves, which is slow. The fact that the LFD is will be tested on this programme too is a very good indication that the test is sensitive enough to be considered. We have already been told this when AS said that using recombinant protein the test sensitivity was in the range of clinical usefullness. I expect both the BAMS test and the LFD to have completed clinical evaluation by the end of august, potentially the BAMS test will be completed in the next couple of weeks.
Neutralising affimers - I don't think much will come of this, it has benefits over the use of antibodies but like many others have said affimers are not yet tested in humans so would probably take a bit longer to develop and I think large pharma may avoid for this reason. I hope I am wrong and there is a chance that I am.
Use in waste water detection - I don't know enough about this really but its always good to have another string to the bow.
Share price - this was moving up gradually in the expectation of news on the LFD and since we didn't get the RNS everyone wanted people sell but nothing negative has actually occurred, in fact quite the opposite. We now have a clear route to clinical testing and one which will be independently validated and also quite rapid.
So far all good news. A lot of people seem to demand 95% sensitivity but I don't think we will get that and I don't think we need to. A rapid test on a massive scale will still be very profitable for company.
Placing - The placing in my opinion was great news. The company is now fully funded, potentially enough to get the first precision drug through phase III trials. My concern before the placing was that the LFD wouldn't be succesful and they would then need to place at a much lower price for the precision platform. This doesn't need to happen now and we got thee funds we needed without placing hundreds of millions of shares. Again very good news. The precision platform is what will make this company
good point. I hadn't thought of this, but then would beads which did a specific RNA pull down not be more efficient?
Hopefully they also have human ACE2 expressing mouse model currently on the go as well. That would be a good next step and relatively inexpensive. That would really bring the large pharma companies knocking on the door
This partly due to inconsistencies with sampling via nasopharngyl method. Hopefully our saliva based methods will be more consistant and sensitive
I would buy these if it meant I could visit a relative who is in the high risk group without fear of passing on the virus to them.
Here's another interesting paper
https:// onlinelibrary.wiley.com/doi/full/10.1002/jmv.25961
https: //jamanetwork.com/journals/jama/fullarticle/2763983
Apologies. Yes it was an uncontrolled test in China but seemed to work. Currently being trialled properly. Will look into it more.
The fact is that the only treatment so far shown to work for covid19 is plasma transfer from recovered patients which is why GSK and AstraZeneca have put money into finding a monoclonal antibody with neutralising properties. If these affimers can do the same at the fraction of cost and massive scalability this really does have enormous potential. Well done avacta. Just wish I had the cash to buy more yesterday.
Well that was an unexpected and extremely welcome RNS.
Will be good to see if we get any collaborators for this.
Large scale manufacturing of the affimers shouldn't be difficult. They are produced by bacterial culture which is much more efficient and cheaper than mammalian cell culture for production of antibodies